三氧化二砷联合载药微球经导管肝动脉化疗栓塞对中晚期肝癌的疗效分析

Clinical analysis of arsenic trioxide combined with drug-loaded microspheres in treatment of advanced liver cancer by transcatheter hepatic artery chemoembolization

目的探讨三氧化二砷联合载药微球经导管肝动脉化疗栓塞对中晚期肝癌的疗效。方法选取郑州大学第一附属医院2017-03—2018-01间收治的90例中晚期肝癌患者作为研究对象。根据随机数表法分为2组,每组45例。2组患者均接受奥沙利铂经肝动脉灌注化疗。研究组使用三氧化二砷与载药微球混悬液栓塞肿瘤供血动脉,对照组使用表柔比星与载药微球混悬液栓塞肿瘤供血动脉。比较2组治疗前及治疗后1个月的肝肾功能、AFP、疾病缓解率(CR+PR)、疾病控制率(CR+PR+SD)。结果2组患者术前、术后1个月的肝肾功能指标及术前的AFP水平等指标比较,差异均无统计学意义(P>0.05)。研究组术后AFP水平明显低于对照组,术后1个月CR+PR和CR+PR+SD均高于对照组,差异均有统计学意义(P<0.05)。结论三氧化二砷联合载药微球经导管肝动脉化疗栓塞,是治疗中晚期肝癌效果较好的方案。

Objective To investigate the clinical efficacy of arsenic trioxide combined with drug delivery microspheres in the treatment of advanced liver cancer by transcatheter arterial chemoembolization.Methods In the first Affiliated Hospital of Zhengzhou University,the 90 cases of middle and late stage liver cancer were treated as the study object in the first affiliated hospital of Zhengzhou University from 2017-03 to 2018-01,and the two groups were divided into two groups according to the random number table method.The study group used arsenic trioxide and drug-loaded microballoon to embolize the tumor blood supply artery,and the control group used epirubicin and drug-loaded microballoon suspension to embolize the tumor blood supply artery.The liver and kidney function,AFP,disease response rate(CR+PR)and disease control rate(CR+PR+SD)were compared in group 2 before and after treatment.Results There was no significant difference in liver and kidney function and AFP level between the two groups before and 1 month after operation(P>0.05).The level of AFP in the study group was significantly lower than that of the control group,and the levels of CR PR and CR PR SD in the study group were higher than those of the control group one month after operation.The difference was statistically significant(P<0.05).Conclusion The combination of arsenic trioxide and drug-loaded microspheres through the transcatheter hepatic arterial chemoembolization is a better treatment for the treatment of advanced liver cancer.